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Abstract
Attempts to express eukaryotic multi-spanning membrane proteins at high-levels have been generally unsuccessful. In
order to investigate the cause of this limitation and gain insight into the rate limiting processes involved, we have analyzed
the effect of translation levels on the expression of several human membrane proteins in Escherichia coli (E. coli). These
results demonstrate that excessive translation initiation rates of membrane proteins cause a block in protein synthesis and
ultimately prevent the high-level accumulation of these proteins. Moderate translation rates allow coupling of peptide
synthesis and membrane targeting, resulting in a significant increase in protein expression and accumulation over time. The
current study evaluates four membrane proteins, CD20 (4-transmembrane (TM) helixes), the G-protein coupled receptors
(GPCRs, 7-TMs) RA1c and EG-VEGFR1, and Patched 1 (12-TMs), and demonstrates the critical role of translation initiation
rates in the targeting, insertion and folding of integral membrane proteins in the E. coli membrane.
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Introduction
High-level expression of eukaryotic multi-spanning membrane
proteins is particularly difficult in E. coli for unknown reasons.
While many eukaryotic proteins can be secreted into the periplasm
in significant quantities, it remains unknown what limits the
accumulation of these polytopic membrane proteins.
Eukaryotic and prokaryotic cells share significant homology in
both co-translational and post-translational membrane protein
insertion mechanisms [1]. In prokaryotes such as E. coli, the post-
translational mechanism is used primarily for secreted periplasmic
proteins while a co-translational mechanism is used for integral
membrane proteins [2]. However, in the cells of higher eukaryotes,
such as mammals, the co-translational system is used almost
exclusively for both integral membrane and secreted proteins.
Co-translational membrane insertion proceeds through several
biochemical steps involving three different protein complexes.
Initially, the signal recognition particle (SRP) recognizes and binds
the first transmembrane or signal peptide domain as it emerges
from the ribosome. A SRP receptor (SR) [1] binds to the SRP and
docks the ribosome with the protein-conducting channel of the
translocon, which creates a pore for insertion of the emerging
polypeptide across the lipid bilayer. The hydrophobicity of a
region of 20 to 40 residues in the emerging N-terminal domain of
the nascent polypeptide determines the engagement of the SRP,
and adjacent charged residues determine the orientation of the
peptide in the cell membrane [3]. It has been shown that certain
components of the E. coli SRP can be functionally substituted for
their eukaryotic homologues [4], emphasizing the similarities of
the two systems.
The number of SRP complexes in eukaryotes suggests one
important difference in protein membrane targeting mechanisms.
Eukaryotic cells typically contain approximately 10,000 copies of
SRP particles or approximately 1 SRP per 10 ribosomes [5]. By
comparison, the prokaryotic SRP is present at much lower copy
number, often just a single SRP per 100 to 1,000 ribosomes, or as
few as 50 particles per cell.
The eukaryotic and prokaryotic SRP also have different
regulatory functions. In E. coli, the Ffh-4.5S RNA component of
the SRP does not contain a functionally analogous region to the
Alu domain of the eukaryotic SRP [6,7] and thus lacks a
corresponding translation pause mechanism.
Further compounding the regulatory differences between
eukaryotes and prokaryotes, translation elongation rates in E. coli
cells can exceed the rate in eukaryotic cells by as much as ten fold.
All of these factors result in an extremely short time period during
which the emerging hydrophobic polypeptide chain in E. coli may
interact effectively with the membrane bound translocation
machinery, unless some other pause mechanism exists.
Several mechanisms have been postulated to explain the
problems with membrane protein expression. These rationales
include available membrane area and protein crowding in the
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1membrane space, general transmembrane protein toxicity [8] and
stability of the protein sequence itself [9]. Since the area of plasma
membrane per volume in a eukaryotic cell is smaller than the area
of plasma membrane per volume in a prokaryotic cell, simply
based on cell size, it is unlikely that the amount of membrane is a
limiting factor in protein expression. Likewise, since several
proteins, the KcsA potassium channel [10], and bacteriorhodopsin
[11], among others, can be expressed at several milligrams per
gram of cell mass, it is unlikely that protein crowding in the plasma
membrane is a limiting factor in expression. Previous attempts to
improve membrane protein expression in E. coli have relied on
selective screening to identify random mutations in specific
bacterial strains [12,13]. With few exceptions, improvements were
limited to bacterial proteins and rarely resulted in increased
expression per cell. Attempts to address expression problems with
simple N or C terminal tags have had limited success [14] while
evaluation of various promoter systems has also shown similar
modest improvement.
Our study focused on determining the influence translation
levels have on the expression of eukaryotic multi-spanning
membrane proteins in E. coli. Using different leaders to control
translation initiation, we show that translation initiation rates
determine both initial induction rates and total protein accumu-
lation. High translation rates quickly lead to a halt in synthesis
while more moderate rates allow for high levels of accumulation
over an extended period of time.
Results
Expression of membrane proteins
Earlier work assessed the expression of CD20, a marker of
human B-cells with four alpha-helical membrane domains [15].
That study demonstrated isolation of milligram quantities of CD20
in a native like conformation from the bacterial membrane,
following expression from a vector previously described for E. coli
protein production. In the current study, we attempted to extend
this work to three new candidate proteins: the human G protein
coupled receptors (GPCRs), RA1c [16,17] and EG-VEGFR1
[18,19,20] with 7-TM domains, and the 12-TM transport like
protein Patched 1 [21,22]. Topology diagrams and molecular
weights of the candidate proteins in their native state are shown in
figure 1. These proteins were chosen solely based on their
biological roles or potential as therapeutic targets.
The three candidate genes were inserted into the original
expression vector under the transcriptional control of the phoA
promoter. In addition, each gene contains nucleotide sequences
encoding a small seven amino acid MKHQHQQ (Uni) leader to
provide an efficient translation initiation. Induction of CD20 and
Patched 1 by means of phosphate limitation resulted in a stable
level of protein expression over time, detectable by anti-his western
(data not shown). However, both GPCR constructs had a
significant toxic effect on the host as demonstrated by the size of
the bacterial colonies (Figure S1). In addition, expression of either
GPCR was problematic and variable due to the poor growth in
even transcription-repressed conditions (Figure 2A). Further, we
observed a striking pattern in the expression time course for both
proteins. Both monomer and dimer forms of the two GPCRs were
stable for about four hours post induction, after which time the
proteins were transformed into high molecular weight aggregates.
This can be clearly seen for RA1c in figure 2B. The time course of
this transition suggests the proteins are correctly membrane
inserted initially, but become highly aggregated over time.
Basal level transcription controlling
Toxicity from basal expression of the GPCR constructs in E. coli
created significant experimental variability, which complicated
any controlled study. To reduce basal transcription, we inserted
the lac operator [23,24] at the +1 position of the existing phoA
promoter [25,26]. The resulting phac promoter requires both
phosphate starvation as well as the addition of the lac inducer,
isopropyl b-D-1-thiogalactopyranoside (IPTG) for full induction
(Figure S2). Partial induction levels can be achieved by
manipulating each regulatory element individually in a lac
repressor iQ strain. To further suppress possible upstream cryptic
promoters, the l to transcriptional terminator [27] was introduced
upstream of the phac to create the tphac promoter. Subsequent work
has shown that the phac and the tphac promoters behave similarly.
The phoA promoter in the GPCR expression constructs was
replaced with the tphac promoter to assess whether or not basal
level toxicity was still a problem. A comparison of the colony sizes
of the E. coli host after transformation with the EG-VEGFR1 and
RA1c plasmids suggested that the tphac promoter had significantly
reduced the toxicity of both genes (shown for RA1c in Figure S1).
The subsequent culture of these colonies in non-inducing
conditions showed that there was no growth retardation with the
tphac promoter as compared to those constructs with the phoA
promoter (Figure 2A). Finally, basal accumulation of the GPCRs
with the phoA promoter was reduced to background with the tphac
promoter (Figure 2C).
Alteration of translation levels
To gain insights into the effects translation levels have on
membrane protein expression, we initially attempted to increase
translation levels to see if these membrane proteins could be forced
into refractile bodies. As the Uni leader is optimized for translation
initiation within the constraints of its coding sequence, we
incorporated a new leader, which had previously been shown to
result in exceptionally high translation levels, the trp LE. The trp
LE was originally isolated as a fusion of the first 9 amino acids of
the trp leader to distal parts of the E protein encoded in the trp
operon [28]. We designed a leader based on the first 79 amino
acids of the LE and fused this to the N-termini of each of the four
studied proteins.
Production of the four membrane proteins with the LE leader
was compared to the original constructs using the smaller Uni
leader. The tphac promoter was induced as noted earlier and a
comparison of the leaders was made at 12 hours post IPTG
addition. All four proteins with the LE leader showed a significant
increase in production as shown in figure 3A. The increase in the
Figure 1. Topology diagram of model human proteins as
expressed in a mammalian cellular plasma membrane. The
predicted molecular weights for these proteins without post-transla-
tional modification are: CD20, 33.0 kDa; EG-VEGFR1, 44.8 kDa; RA1c,
35.5 kDa and Patched 1, 160.5 kDa.
doi:10.1371/journal.pone.0035844.g001
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higher than expected for a modest change in translation initiation
rates. Expression levels of these membrane proteins with the Uni
leader were also compared to constructs with no leader. The lack
of a leader resulted in very low expression compared to the Uni
with CD20, RA1c and EG-VEGFR1, while Patched 1 expression
was modestly higher than that observed with the Uni leader
(Figure S3). However, because the translation initiation rates of the
constructs without leaders are unknown, it is difficult to interpret
these results.
Control experiments fusing the native Met Patched 1 translation
initiation region (TIR- first seven residues) to an unrelated protein
EGFL7 show that the native Patched 1 TIR is extremely weak,
and no translated protein could be detected in experiments similar
to those shown in figure 3B (data not shown). The first 160 base
pairs at the start of the Patched 1 gene are highly G/C rich (79%),
and significant mRNA secondary structure would be expected to
inhibit translation initiation at the planned start for the Met
construct, and possibly the Uni construct. The most likely
explanation for the minor expression observed from the native
Met Patched 1 TIR in figure S3 is internal translation from
Met152, which possesses a good Shine-Dalgarno just upstream.
Translation from this residue is consistent with the observed
molecular weight.
Comparison relative translation rates
In order to compare the relative translation initiation rates for
the two leaders, CD20 synthesis rates were determined early in the
induction. Cells were induced for 30 minutes after which samples
were removed for western blot analysis of CD20 accumulation
with each leader. The culture was then labeled with
35S cysteine
for 5 minutes, and his-tagged CD20 was isolated by Ni-NTA
resin. After separation by SDS-PAGE and transfer to nitrocellu-
lose, CD20 was visualized either by anti-his western blot or
autoradiography. Surprisingly, the results shown in figure 3B
reveal that the Uni leader has a higher translation rate than the LE
leader early in the induction. A similar experiment with the two
Figure 2. Improved cell growth and general accumulation of
integral membrane proteins using a dually regulated promot-
er. (A) Restricted E. coli growth in LB with the phoA-RA1c construct is
relieved by using the tphac promoter, which reduces basal level
expression. A 24-hour growth curve shows the empty pBR322 vector
control (blue triangles), phoA-RA1c expression construct (green
diamonds), tphac-RA1c expression construct (red circles) and phoA-
EGFL7 as a non-membrane protein control (brown squares). (B)A
representative western blot of RA1c expression from the phoA
promoter is shown following induction by phosphate depletion when
the cells reach approximately 2 OD600 (time 0). Maximum expression is
reached within two hours post induction. By 6 hours, aggregation has
begun and by twelve hours almost all the protein has moved from the
monomer band to high molecular weight aggregate. Basal expression is
shown after overnight growth in LB medium (LBON). The western blot
was probed with an HRP coupled anti-his antibody. (C) A comparison of
basal expression in LB of the GPCR proteins, RA1c and EG-VEGFR1, from
the phoA and tphac promoters by western blot analysis. The phoA
constructs show significant accumulation levels of the membrane
proteins while the tphac constructs have reduced the accumulation to
background levels. The arrow points to the monomer protein band.
doi:10.1371/journal.pone.0035844.g002
Figure 3. Improved integral membrane protein expression with
the LE leader. (A) Comparison of the expression levels with the Uni
and the LE leaders for multi-spanning membrane proteins CD20, RA1c,
EG-VEGFR1 and Patched 1. Arrows point to the monomer protein bands
for the two GPCRs. (B) The Uni leader has a higher translation rate than
the LE leader at the beginning of the induction, but the rates reverse by
the end of the induction. Relative translation rates were measured by
pulse labeling cells expressing CD20 with
35S cysteine for five minutes
as well as by assessing accumulation levels in whole-cell extracts by
immunoblot with HRP conjugated anti-His antibody. The non-
membrane protein EGFL7 was used as a control.
doi:10.1371/journal.pone.0035844.g003
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EGFL7, a protein which aggregates in the cytoplasm. Again, the
Uni leader reveals a stronger translation rate than the LE leader
(Figure 3B). However, if the CD20 culture is pulse-labeled for
5 minutes with
35S cysteine later in the induction (14 hours post
IPTG addition), then the translation rate for the LE leader is much
higher than that observed for the Uni leader (Figure 3B).
Immediately following induction, translation from the Uni
leader is higher than from the LE leader; however, the relative
rates of the two leaders reverse over time. To examine this
observation in more detail, the induction of CD20 or EG-
VEGFR1 fused to each of the two leaders was repeated and
samples were removed at numerous time points. These samples
were analyzed by SDS-PAGE followed by anti-His western
blotting to visualize CD20 and EG-VEGFR1 accumulation. As
shown in figure 4A and B, the accumulation of both CD20 and
EG-VEGFR1 reaches a maximum after approximately 30 min-
utes with the Uni leader. By contrast, accumulation of both
membrane proteins from the LE leader increased over several
hours to outpace accumulation from the Uni leader.
Leader amino acid sequence and size are not important
To confirm that the translation initiation rate is the crucial
variable in expression of these membrane proteins, the length of
the LE leader was evaluated for effects on protein accumulation. A
series of deletions at the C-terminus of the LE leader were created
while preserving the TIR [29] in the first several codons. These
constructs were fused to the N-terminus of CD20 and analyzed for
their ability to accumulate protein. The results shown in figure 4C
reveal that CD20 accumulation does modestly and gradually
decrease with size. However, even at the smallest size of 10 amino
acids, the accumulation of CD20 with the LE leader is significantly
greater than that of the Uni leader (7 amino acids). This suggests
that the core TIR of the leader is important for membrane protein
accumulation presumably as a function of translational strength.
The results imply that the weaker TIR of the LE leader allows
continuous membrane protein accumulation over several hours of
induction while the stronger TIR of the Uni leader produces an
early overload and collapse of the membrane targeting system.
Therefore, if transcription levels were equivalently reduced for
both leaders, then overload of the membrane targeting system
would be avoided and the Uni leader should surpass the LE leader
in membrane protein accumulation. To test this hypothesis,
cultures with either the Uni or the LE leader fused to CD20 under
the control of the tphac promoter were induced by phosphate
starvation for 16 hours. Without the addition of IPTG to remove
the lac repressor control, a partial induction is achieved, leading to
an equivalent drop in transcription/translation in each cell. The
results shown in figure 4D bear out this prediction with the Uni
leader, resulting in greater membrane protein accumulation than
that observed with the LE leader and rule out anything special
about their actual amino acid sequences.
Membrane association of over-expressed proteins
To ascertain the native like expression of proteins fused to the
LE leader, the sub-cellular localization of the proteins was
evaluated by equilibrium ultracentrifugation as previously de-
scribed [15]. Correctly localized membrane proteins should
migrate with the bacterial membranes to a density of less than
1.29 g/cm
3 (1.75 M sucrose layer), while typical soluble or
retractile body proteins, if present, lack membrane association
and have a density between 1.33–1.42 g/cm
3 and will migrate to
the bottom of the sucrose gradient. The results shown in figure 5A
indicate that all four LE tagged proteins migrate to above the
1.29 g/cm
3 density layer, consistent with the 1.15–1.25 g/cm
3
density of the E. coli membrane [30].
Correct membrane orientation
To determine if the GPCRs with the LE leader are correctly
oriented in the cytoplasmic membrane, a FLAG tag was added to
either the N- or C- termini of EG-VEGFR1 and the extracellular
localization of the FLAG tag was evaluated by immuno-
precipitation of E. coli spheroplasts expressing either constructs
[31]. These results shown in figure 5B-II demonstrate equivalent
expression of both constructs. The FLAG antibody binds to LE-
EG-VEGFR1 only when the FLAG tag is expressed at the N-
terminus as predicted for a GPCR; however, no binding is
observed for LE-EG-VEGFR1 with the FLAG tag at the C-
terminus (Figure 5B-III). This indicates the FLAG tag is
unavailable for binding, which is consistent with the cytoplasmic
localization of EG-VEGFR1 C-terminus (Figure 5B-I). To confirm
that the FLAG tag on LE-EG-VEGFR1 is equally accessible to
Figure 4. Leader dependent accumulation of CD20 and EG-
VEGFR1 following induction of the tphac promoter. (A) Protein
accumulation maximizes within thirty minutes of induction with the Uni
leader. (B) Protein accumulation continues over 20 hours after
induction with the LE leader. (C) The effect of C-terminal truncations
on expression from the LE leader. The full 79 amino acid LE leader was
truncated from the C-terminus to observe the importance of the
translation initiation rate as compared to the length of the LE leader.
Truncated leaders were fused to CD20 and the whole cell lysates were
immunoblotted with HRP conjugated anti-His antibody. Two film
exposures are shown. (D) Reduced promoter activity results in reversal
of the relative expression levels from the Uni and the LE leaders fused to
CD20. Cultures were grown under partial promoter induction and the
whole cell lysates were probed with HRP conjugated anti-His antibody
for detection.
doi:10.1371/journal.pone.0035844.g004
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E. coli membrane proteoliposomes where both sides of the
membrane are accessible. In each case, approximately equivalent
amounts of FLAG antibody were recovered by immuno-
precipitation (Figure S4) Addition of the detergent Triton X-100
did not further enhance accessibility of the FLAG tag, as might be
expected.
Cell membrane expression of CD20
To confirm native folding and membrane expression of human
CD20 in a cellular context, spheroplasts of E. coli expressing CD20
were evaluated by fluorescent activated cell sorting (FACS) [32]
using the conformation dependent antibody rituximab [33]. The
second of the two extracellular loops of CD20 is the binding site
for rituximab and this interaction is strongly dependent on the
native conformation stabilized by a disulfide bond. FACS analysis
showed a large shift in mean fluorescent intensity for CD20
expressing cells as compared to control cells shown in figure 6. The
data is consistent with localization of CD20 to the cytoplasmic
membrane and correct native like folding of the second
exracellular loop of CD20.
Figure 5. Membrane localization, cell surface expression and orientation of integral membrane proteins expressed with the LE
leader. (A) Over-expressed LE tagged proteins are localized to the membrane fraction in sucrose density gradient centrifugation. The insoluble non-
membrane protein EGFL7 has been included as a control. Each lane represents fractions removed from the sucrose gradient and analyzed by SDS-
PAGE anti-his immunoblot. (B) Orientation in the E. coli membrane was established by creating two constructs of EG-VEGFR1 with a FLAG-tag epitope
at either the N or C terminus. {I} GPCR transmembrane proteins are known to have an exposed N-terminus on the surface of cells. {II} EG-VEGFR1
constructs containing the FLAG-tag epitope at either the N or C terminus express at similar levels in E. coli as confirmed by anti-his immunoblot of
whole cell lysates. {III} Only spheroplasts of cells expressing the FLAG tag epitope at the exposed N-terminus were able to pull-down anti-FLAG
antibody as detected by anti-murine IgG HRP conjugated antibodies.
doi:10.1371/journal.pone.0035844.g005
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Extraction of proteins using native detergents confirmed the
high expression levels with the LE leader and the phac promoter.
Western blots suggest that approximately 90% of CD20, RA1c or
EG-VEGFR1 are extracted in Fos-Choline 12 (FC12); however,
Patched 1 is largely resistant to extraction in this detergent. In
addition, LE-CD20 can be extracted in a mixture of FC12 and
dodecyl maltoside (DDM) detergents (Figure S5) further indicating
a native like conformation of this protein in the membrane [34].
The detergent FC12 has demonstrated excellent properties for
solubilizing the E. coli membrane [35], and Fos-Choline detergents
and FC12 have shown favorable properties for the isolation of
eukaryotic membrane proteins [36] including GPCRs [37].
Expression of LE-CD20 can be detected in coomassie stained
whole cell extract, while the GPCR proteins require additional
enrichment using Ni-NTA resin (Figure 7A). Single step IMAC
purification of all three proteins provide 2 to 10 mg of protein per
liter at greater than 90% purity as estimated from coomassie
stained gels (Figure S6). Large and small-scale isolations of CD20,
RA1c, and EG-VEGFR1 (Table S1) show yields are reproducible
within two fold. Quantification of LE-CD20 expression levels in
whole cell extracts against a standard curve of purified LE-CD20
show total cellular expression levels to be 41 mg/L (Figure S7 and
Methods S1), indicating 25% protein recovery after primary
purification. We estimate recovery of EG-VEGFR1 and RA1c to
be similar. The high LE-CD20 expression levels translate to 3610
5
molecules per cell – consistent with FACS data.
Characterization of LE-CD20
Earlier functional expression and purification of CD20
demonstrated isolation of 10–20 mg of His-tagged protein from a
gram of E. coli cells. For comparison, LE tagged human CD20,
under the transcriptional control of the tphac promoter, was
expressed in E. coli and isolated from cell membranes by IMAC
affinity chromatography followed by thrombin cleavage of the LE
leader and size exclusion chromatography. Representative samples
of purified his-tagged human CD20 are shown in the SDS
polyacrylamide gel in figure 7B. CD20 isolated in this relatively
simple manner is over 95% pure with a final yield better than
5 mg/L of protein in shake-flasks or 1 mg/g cells. The protein
migrates with an apparent molecular weight of approximately
35 kDa under reducing conditions, which is in reasonable
agreement with the calculated molecular weight of 33 kDa. In
both reducing and non-reducing SDS-PAGE, purified LE-CD20
shows significantly fewer contaminating protein bands and less
protein aggregate than Uni-CD20, consistent with the improved
expression properties of LE-CD20.
To confirm proper folding and processing of LE-CD20, the
presence of the disulfide bond in the extracellular domain of CD20
was evaluated using the conformation specific antibody rituxmab
[33] in the ELISA assay described previously [15]. In this assay,
rituximab binds LE-CD20 with an EC50 of 0.77 nM (Figure 7C).
This affinity is tighter than the binding of rituximab to control
Uni-CD20 of 3.1 nM and in reasonable agreement with
previously reported data [15]. As an additional control, LE-
CD20 was reduced and alkylated and assayed for rituximab
binding. This procedure eliminates rituximab binding, thus
Figure 6. Expression and folding of CD20 in the E. coli inner
membrane. Cell surface expression and orientation of CD20 was
assessed from spheroplasts of E. coli cells expressing either Uni-CD20
(blue), LE-CD20 (green) or an empty control vector (red) treated with
Alexa-488 conjugated anti-CD20 antibody to the extracellular loop of
CD20 and analyzed by flow cytometry.
doi:10.1371/journal.pone.0035844.g006
Figure 7. Protein expression, isolation and characterization. (A)
CD20 (left most panel) could be seen in whole cell extracts, while RA1c
and EG-VEGFR1 (right panel) required purification on Ni-NTA resin. (B)
Coomassie-stained SDS gel of purified CD20. Lane 1) LE-CD20 non-
reduced; 2) Uni-CD20 non-reduced; 3) Molecular weight markers: 200,
116, 97, 66, 55, 36.5, 31, 21.5 14.4 6 kDa; 4) LE-CD20 reduced; 5) Uni-
CD20 reduced. (C) Activity of Uni and LE human CD20. Activity of the
isolated proteins was assayed using the conformation specific antibody
rituximab. Binding to LE-CD20 (solid black line, solid squares), Uni-CD20
(dashed line, solid circles), reduced and alkylated LE-CD20 (negative
control) (solid gray line, open squares), and (control) PBS (solid black
line, open circles). The curves for rituximab binding were determined
from a 4-parameter fit and the LE leader was cleaved from CD20 before
analysis.
doi:10.1371/journal.pone.0035844.g007
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disulfide bond.
Ligand binding to LE-EG-VEGFR1
To demonstrate proper folding and function of one of the
GPCRs, we evaluated ligand binding to LE-EG-VEGFR1 (RA1c
has no known ligand). EG-VEGF (Prokineticin 1) was incubated
with E. coli membrane proteoliposomes prepared from negative
control cells and cells expressing LE-EG-VEGFR1 fused to a
FLAG epitope at either the N or the C terminus. These
membranes were extensively washed, pelleted by centrifugation
and analyzed by SDS-PAGE and developed by immuno-blot using
an antibody to EG-VEGF. As shown in figure 8, the EG-VEGF
ligand binds to LE-EG-VEGFR1 membrane proteoliposomes,
indicating at least some population of the receptor is properly
folded.
Although experimental conditions limit exact quantitation of
the amount of ligand bound to the receptor, we estimate the
amount of receptor bound EG-VEGF in these experiments at
2610
3 molecules/cell, from a series of known concentrations of
the ligand. Based on our results for receptor expression and
recovery (Table S1 and Figure S7), we estimate the receptor at
approximately 9610
3–4610
4 molecules/cell. Accounting for the
loss of correct orientation of the receptor in the membrane
following generation of proteoliposomes, we estimate that 10–40%
of the receptors are able to bind ligand.
Discussion
The expression of eukaryotic multi-spanning membrane
proteins in E. coli is particularly difficult compared to the relative
ease of producing cytoplasmic and secreted proteins. A number of
efforts have been undertaken in different labs to identify and
overcome the expression barrier with this class of proteins. This
work includes the use of special bacterial strains [12], reduced
transcription [13], proteomic analysis upon induction [8] and a
variety of different affinity tags [14]. However, with the exception
of a recent report involving the directed evolution of a GPCR that
resulted in greater expression and stability [9], accumulation of
these proteins per cell remained about the same. Additionally, the
underlying molecular limitation of expression has remained
elusive.
Our study focused on the relationship between translation levels
and the expression or accumulation of these membrane proteins in
E. coli. Since translation levels are largely determined by the
translation initiation rate, we began by comparing the expression
of four mammalian multi-spanning membrane proteins fused to
two previously described leaders, the Uni and the LE. The
resulting expression per cell of membrane proteins with the two
leaders varied by 1–2 orders of magnitude – a much larger than
expected difference considering that both leaders were thought to
have similar high translation rates. Subsequent analysis revealed
that the LE leader, which produced much higher levels of
membrane protein expression, actually had a translation initiation
rate that was several fold lower than that of the Uni leader.
A detailed look at the expression profile shows that the Uni
leader with its stronger translation rate does indeed outpace the
weaker translating LE leader very early in the induction. However,
after approximately 30 minutes, membrane protein expression
with the Uni leader slowed significantly with no further increase in
protein accumulation. By contrast, the LE leader membrane
protein expression and accumulation continued without change
for several hours. This allowed the more slowly translating LE
leader membrane proteins far greater total production than the
initially highly translating Uni leader membrane protein.
All four highly expressed mammalian proteins with the LE
leader are membrane associated upon cell fractionation, and
inserted with a native like structure in the cell membrane. We
analyzed the orientation of one of the GPCRs, EG-VEGFR1. The
N-terminus of this receptor is orientated towards the periplasm
while the C-terminus is cytoplasmic as is expected for proper
insertion. The receptor also shows binding to its ligand, EG-
VEGF. Additionally, CD20 has the correct orientation in the
membrane based on FACS analysis and rituximab antibody
binding.
The effect of translation levels on multi-spanning membrane
protein expression can be quite significant and this needs to be
understood at the molecular level. The most likely explanation for
our observations is a potential bottleneck at the level of membrane
targeting, presumably by the SRP. Translation at too high of a
rate would be expected to overload the more limited co-
translational secretory pathway in E. coli and quickly lead to a
halt in translation as we observe with the Uni leader. A more
moderate level of translation seen with the LE leader avoids an
overload of this pathway, allowing for membrane targeting and
insertion over longer periods of time. The halt in translation
observed with the Uni leader soon after promoter induction
suggests that there is a mechanistic membrane protein targeting-
translation coupling that is maintained in the cell, although, the
exact molecular nature of this coupling remains to be determined.
Optimizing integral membrane protein accumulation could
potentially be controlled at the level of transcription to achieve the
desired translation rate. The promoter sequence could be modified
to provide a specific transcriptional strength, or alternatively
repressor controlled promoters could be induced with suboptimal
inducer concentrations. This later approach, however, requires the
deletion of inducer transporters [38] and limits host strain
selection.
Materials and Methods
All E. coli experiments used the 58F3 strain which was derived
from W3110 and has the following genotype Dfhu (DtonA) Dlon galE
rpoHt (htpRts) DclpP lacIq DompTD(nmpc-fepE) DslyD.
All detergents were obtained from Anatrace, Inc., Maumee,
OH. Unless otherwise mentioned, all chemicals were obtained
from Sigma-Aldrich, St. Louis, MO.
Figure 8. Ligand binding to the GPCR, LE-EG-VEGFR1. E. coli
membrane proteoliposomes were treated with thrombin to remove the
LE-leader and incubated overnight at 4uC with EG-VEGF in PBS. Pelleted
membranes were separated by SDS-PAGE and developed by immuno-
blot using an anti-EG VEGF antibody. Samples are: lane 1) pBR322
negative control; 2) LE-EG-VEGFR1, N-terminal FLAG; 3) LE-EG-VEGFR1,
C-terminal FLAG. The location of EG-VEGF (molecular weight 9 kDa) is
indicated by an arrow.
doi:10.1371/journal.pone.0035844.g008
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turing, anti-His from Roche, anti-FLAG M2 from Sigma and anti-
Prokineticin 1 from Novus Biologicals.
Cloning and Expression
The cDNA for human CD20, RA1c, EG-VEGFR1, and
patched 1 were sub-cloned, using standard molecular biology
techniques, into a pBR322-derived plasmid containing the b-
lactamase gene and tRNA genes for three rare E. coli codons (argU,
glyT and pro2). A short Uni (MKHQHQQ) and 79 amino acid LE
sequence were added to the N-terminus of the membrane proteins
and an octa-His sequence was placed at the C-terminus to aid in
detection and purification. A thrombin cleavage site (LVPRGS)
has been placed after the LE leader to allow removal of the leader
sequence. Gene transcription is under control of the phoA, phac or
tphac promoter. Gene expression was induced by dilution of a
saturated LB carbenicillin culture into C.R.A.P. phosphate
limiting media [39]. The culture was then grown at 30uC for
24 hours or the specified time for the phoA promoter. The Pho
regulon generally turns on approximately 7–8 hours post dilution
when the cell density reaches an optical density at 600 nm (OD600)
of 2. For the tphac promoter induction, cultures were induced at
OD600 of 2 with 1 mM IPTG for 6 to 10 hours or the time
specified. Human CD20 cysteine residues 111 and 220 were
mutated to serines by site directed mutagenesis to improve protein
behavior during purification.
Protein Purification
To determine protein location by detergent solubility, cells were
lysed in buffer B (20 mM Tris, pH 7.5, 300 mM NaCl) by
sonication and the membrane fraction was isolated by centrifu-
gation. The membrane pellet was then re-suspended in buffer B
and 1% Fos-Choline 12 (FC-12) and extracted overnight at 4uC.
Samples were then centrifuged at 100,0006g for 1 hour and the
supernatants collected. As necessary, the detergent soluble fraction
was further purified using Ni-NTA Phynexus (San Jose, CA)
pipette tips according to the manufacture’s instructions.
For large-scale extraction, cells were re-suspended in 10 mL/g
buffer A (20 mM Tris, pH 7.5, 5 mM EDTA) and centrifuged at
12,0006g for 30 min. The cell pellet was then re-suspended in
buffer B (see above), lysed by cell disruption using a microfluidizer
(Microfluidics Corp., Newton, MA) and centrifuged at 125,0006g
for 1 hour. To extract the membrane protein from the cell
membrane, the pellet was re-suspended in buffer B, FC-12 was
added to 1% and the solution was stirred overnight at 4uC. The
next day, the detergent insoluble fraction was pelleted by
ultracentrifugation at 125,0006g for 1 hour. The supernatant
was loaded onto a Ni-NTA Superflow (Qiagen Inc. Valencia, CA)
column pre-equilibrated in buffer B containing 5 mM FC-12
(buffer C). The column was washed with 10 column volumes of
20 mM imidazole in buffer C and eluted with buffer C with
250 mM imidazole. All purification steps through column loading
were performed at 4uC.
Eluent fractions containing CD20 were concentrated and
loaded onto a Superdex 200 column (Amersham Biosciences,
Piscataway, NJ) pre-equilibrated in buffer C. The his-tagged
human CD20 was further purified over a 5 mL HiTrap HP Q
(Amersham Biosciences, Piscataway, NJ) column prior to gel
filtration. For LE-CD20, the LE leader was removed by thrombin
before size exclusion chromatography.
For detergent exchange, samples were passed over a Superdex
200 column in 0.1% dodecyl maltoside, 150 mM NaCl, 20 mM
HEPES, pH 7.2. Alternatively, samples were bound to a small Ni-
NTA column, washed with buffer B and detergent and eluted in
buffer B with detergent and 300 mM imidazole. These samples
were then dialyzed against buffer B and detergent to remove
imidazole.
Density Gradient Centrifugation
A discontinuous sucrose gradient was generated by layering
1.75, 1.4 and 0.8 M sucrose solutions of Buffer D (150 mM NaCl
and 20 mM HEPES, pH 7.2) in centrifuge tubes. E. coli
membrane proteoliposome preparations were prepared by cell
disruption in buffer D (10 mL/g) containing 1 mM EDTA. The
insoluble fraction was isolated by centrifugation at 38,0006g for
1 hour. The supernatant was discarded and the pellet was re-
suspended in Buffer D containing 0.25 M sucrose. This re-
suspension was mixed with 1.9 M sucrose solution, resulting in
final concentration of 1.75 M sucrose. 1 mL of this mixture was
then placed at the bottom of a centrifuge tube and equal volumes
of the 1.4 M and 0.8 M sucrose solutions were layered above.
Samples were centrifuged for 1 hour at 100,0006g. Samples in
200 mL aliquots were removed from the top of the tube and
analyzed by SDS-PAGE, transferred to nitrocellulose and probed
with horseradish peroxidase conjugated anti-his antibody.
ELISA Assays
96 well plates were coated overnight at 4uC with 100 mLo f
CD20 at 1 mg/mL in PBS with solubilizing detergent diluted to
below its critical micelle concentration. Plates were then washed
three times with PBS containing 0.05% Tween 20 (PBST) and
blocked for 45 minutes at room temperature with 200 mL of PBST
containing 0.5% BSA (blocking and assay buffer). Plates were
washed again three times with PBST and probed with the primary
antibody. 150 mL of rituximab at 60 mg/mL in assay buffer was
added to the appropriate wells and three fold serial dilutions were
performed in the subsequent wells by taking 50 mL from the first
well and mixing with 100 mL of assay buffer in the next and
subsequent wells to a final concentration of approximately 2 ng/
mL. After 90 minutes incubation at room temperature, the plates
were washed with PBST and bound rituximab was detected with
100 mL of horseradish peroxidase conjugated goat anti-human
F(ab9)2 (Jackson ImmunoResearch Laboratories Inc, West Grove,
PA) diluted 1:2,000 in assay buffer, washed six times with PBST
and developed with 100 mL/well of TMB Microwell Peroxidase
Substrate System (KPL, Gaithersburg, MD) mixed according to
the manufacturer’s instructions. The reaction was halted by the
addition of 100 mL/well of 1.0 M phosphoric acid and the
absorbance was measured at 450 nm using a plate reader.
Reduced and alkylated CD20 samples were prepared by
reduction with 10 mM DTT and alkylation by addition of
25 mM iodoacetamide. The reaction was halted by a further
addition of 100 mM DTT. Following each step, the reaction was
allowed to proceed for 30–60 minutes at room temperature at
pH 8.0. EC50 values were determined by 4-parameter fit of the
data.
FACS Analysis
For preparation of spheroplasts, 5 OD600 mL of induced cells
were recovered from expression media by centrifugation for
5 minutes at 5,000 rpm in a tabletop rotor (4,0006g). The
supernatant was discarded and the pellet was re-suspended in
350 mL of ice-cold spheroplast preparation buffer A (50 mM Tris-
HCl, pH 8.0, 25% sucrose, 100 mg/mL lysozyme, 67 mL/mL
complete EDTA free protease inhibitor tablet in 2 mL deionized
H2O) and the solution was diluted with 700 mL of ice-cold 1 mM
EDTA. This mixture was allowed to incubate for 10 minutes at
room temperature. 50 mL of 0.5 M MgCl2 was then added to
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for 10 minutes.
To block non-specific binding, the spheroplasts were pelleted at
5,000 rpm for 5 minutes in a tabletop centrifuge, gently re-
suspended in 0.5 mL of ice-cold 10% fetal bovine serum in PBS
and incubated on ice for 10 minutes. Spheroplasts were stained by
addition of Alexa 488 conjugated anti-CD20 antibody at a
concentration of 10 mg/mL followed by incubation at room
temperature for 1 hour with mild agitation. Spheroplasts were
pelleted as before and washed three times with 500 mL of PBS.
Cells were analyzed on an EPIC-XL fluorescently activated cell
sorter with the gating area adjusted for the size of the E. coli cells.
35S Pulse-Labeling
Cultures were induced for 30 minutes (14 hours for the late
time point) with 1 mM ITPG at an OD600 of 2 and pulsed with
35S cysteine for 5 minutes. SDS was added to a final concentration
of 2% to stop the labeling and then heated immediately at 95uC
for 15 minutes to lyse the samples. The samples were then diluted
with 2% FC-12 in PBS to bring down the SDS concentration to
0.2% so that they could be loaded onto a Ni-NTA spin column
(Qiagen) and purified using a standard protocol provided by
Qiagen. Eluates were separated by SDS-PAGE, transferred to
nitrocellulose and exposed to a film.
Supporting Information
Table S1 Primary Protein Recovery. Summary of protein
yields after IMAC affinity purification from small-scale, 100 mL
and large-scale, greater then 1 L expression.
(TIF)
Figure S1 Restricted E. coli growth and small colony
size formation following cell transformation with a
multi-spanning membrane protein construct. Basal pro-
tein expression from the phoA promoter is deleterious to cell
growth. (a) vector control (b) phoA-RA1c expression construct
uninduced (c) tphac-RA1c expression construct uninduced.
(TIF)
Figure S2 Nucleotide sequence of the phoA, phac and
tphac promoters. (a) The phoA promoter showing the pho box
and 210 sequences underlined (b) The dually regulated phac
promoter showing the introduced lac operator underlined (c) The
tphac promoter showing the addition of the l to transcriptional
terminator upstream of the phac promoter. PhoA 210 sequence
and Pho Box (blue), Lac operator (red), Lambda transcription
terminator (brown), ATG translation start (green).
(TIF)
Figure S3 Membrane protein expression without a
leader. Comparison of the expression levels with the Uni and
leaderless (Met) constructs for multi-spanning membrane proteins
CD20, RA1c, EG-VEGFR1 and Patched 1. Arrows point to the
monomer protein bands for the two GPCRs.
(TIF)
Figure S4 N and C-terminal FLAG epitopes of LE-EG-
VEGFR1 are accessible to anti-FLAG antibody. Membrane
proteoliposomes were prepared from E. coli expressing either N or
C terminal FLAG tagged LE-EG-VEGFR1. Samples are: lane 1)
pBR322 negative control; 2) LE-EG-VEGFR1, N-terminal FLAG;
3) LE-EG-VEGFR1, C-terminal FLAG; 4) pBR322 negative
control; 5) LE-EG-VEGFR1, N-terminal FLAG; 6) LE-EG-
VEGFR1, C-terminal FLAG. Samples for lanes one, two and
three were treated with 1% Triton X-100 prior to incubation with
anti-FLAG antibody. Samples for lanes four, five and six were
treated with antibody in the absence of detergent.
(TIF)
Figure S5 Extraction of LE-CD20 from the cell mem-
brane. Samples of E. coli membrane with expressed LE-CD20
were treated with a ratio of detergents from 1% FC-12 to 1%
DDM. Lane 1) 1% FC-12; 2) 0.75:0.25; 3) 0.5:0.5; 4) 0.25:0.75; 5)
1.0% DDM. Membrane samples were extracted with detergent
over night and CD20 was detected using an anti-His HRP
conjugated antibody.
(TIF)
Figure S6 Representative gels of membrane proteins
following large-scale purification over immobilized
nickel column. Samples were detected by coomassie staining
following separation on 4 to 20% SDS-PAGE. Samples are: lane
1) LE-CD20; 2) Molecular weight marker; 3) LE-EG-VEGF-R1;
4) LE-RA1c; 5) Molecular weight markers. Each sample lane
contains 15 mg of protein. Molecular weights of the protein
standards are shown on side of the figure.
(TIF)
Figure S7 LE-CD20 is expressed at high levels in E. coli.
Total cellular level of LE-CD20 was determined by comparison to
a standard curve generated with the purified protein. Based on the
average OD600 of 3.0 for the LE-CD20 culture, total expression is
41 milligrams per liter of culture. Representative data from two
independent measurements is shown. *Lane quantitation was
determined using Licor-700.
(TIF)
Methods S1 Methods for quantitation of LE-CD20
expression levels in E. Coli.
(DOC)
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